Whereas, after cycle 1, the incidences of all‐grade neutropenia (29.1% vs. 24.6%; p = 0.020), thrombocytopenia (5.4% vs. 2.6%; p = 0.001), alanine aminotransferase elevation (8.2% vs. 4.9%; p = 0.002), and hyperbilirubinemia (2.2% vs. 1.0%; p = 0.027) were higher in the post‐reimbursement group than those in the pre‐reimbursement group, their frequency became lower in the post‐reimbursement group (18.5% vs. 22.0% for neutropenia; p = 0.037) or similar between both groups after cycle 2. This evidence concerns the gene GPT and Hyperbilirubinemia.